Your browser doesn't support javascript.
loading
Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States.
Oladipupo, Fathia; Stanek, Joseph; Walden, Joseph; Young, Jennifer; Rose, Melissa J; Nicol, Kathleen; Villella, Anthony; Creary, Susan.
Affiliation
  • Oladipupo F; Department of Pediatrics, Center for Child Health Equity Outcomes and Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Stanek J; Department of Pediatrics, Nationwide Children's Hospital, Division of Hematology/Oncology/BMT, Columbus, Ohio, USA.
  • Walden J; Department of Pediatrics, Center for Child Health Equity Outcomes and Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Young J; Department of Pediatrics, Nationwide Children's Hospital, Division of Hematology/Oncology/BMT, Columbus, Ohio, USA.
  • Rose MJ; Department of Pediatrics, Nationwide Children's Hospital, Division of Hematology/Oncology/BMT, Columbus, Ohio, USA.
  • Nicol K; Department of Pathology & Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Villella A; Department of Pediatrics, Nationwide Children's Hospital, Division of Hematology/Oncology/BMT, Columbus, Ohio, USA.
  • Creary S; Department of Pediatrics, Center for Child Health Equity Outcomes and Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Pediatr Blood Cancer ; 71(6): e30945, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38462769
ABSTRACT
Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was not associated with being prescribed a lower HU dose or having increased acute SCD visits early in the HU treatment course. Future studies are needed to confirm these findings in older children with SCD.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Duffy Blood-Group System / Hydroxyurea / Anemia, Sickle Cell / Antisickling Agents Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: America do norte Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Duffy Blood-Group System / Hydroxyurea / Anemia, Sickle Cell / Antisickling Agents Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: America do norte Language: En Year: 2024 Type: Article